Literature DB >> 20719400

Clinical determinants of aspirin resistance in diabetes.

Hussein N Yassine1, Grace Davis-Gorman, Craig S Stump, Stephen S Thomson, Justin Peterson, Paul F McDonagh.   

Abstract

Recent studies indicate that not all diabetic subjects benefit from aspirin therapy. Our objective is to characterize diabetic subjects with aspirin resistance using urine thromboxane, and VerifyNow measures. Our results suggest that cardiovascular disease, microalbuminuria, poor diabetes control, and increased waist circumference help identify aspirin resistance in diabetes.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20719400      PMCID： PMC2962939          DOI： 10.1016/j.diabres.2010.07.008

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  14 in total

Review 1.  Aspirin and clopidogrel resistance: an emerging clinical entity.

Authors:  Thomas H Wang; Deepak L Bhatt; Eric J Topol
Journal:  Eur Heart J       Date:  2005-12-19       Impact factor: 29.983

Review 2.  Aspirin resistance.

Authors:  Huyen A Tran; Sonia S Anand; Graeme J Hankey; John W Eikelboom
Journal:  Thromb Res       Date:  2007-01-22       Impact factor: 3.944

3.  Platelet activation in obese women: role of inflammation and oxidant stress.

Authors:  Giovanni Davì; Maria Teresa Guagnano; Giovanni Ciabattoni; Stefania Basili; Angela Falco; Marina Marinopiccoli; Michele Nutini; Sergio Sensi; Carlo Patrono
Journal:  JAMA       Date:  2002 Oct 23-30       Impact factor: 56.272

4.  Identification of individuals with insulin resistance using routine clinical measurements.

Authors:  Steven E Stern; Ken Williams; Eleuterio Ferrannini; Ralph A DeFronzo; Clifton Bogardus; Michael P Stern
Journal:  Diabetes       Date:  2005-02       Impact factor: 9.461

5.  Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina.

Authors:  F Cipollone; G Ciabattoni; P Patrignani; M Pasquale; D Di Gregorio; T Bucciarelli; G Davì; F Cuccurullo; C Patrono
Journal:  Circulation       Date:  2000-08-29       Impact factor: 29.690

6.  Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.

Authors:  John W Eikelboom; Jack Hirsh; Jeffrey I Weitz; Marilyn Johnston; Qilong Yi; Salim Yusuf
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

7.  A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.

Authors:  Marie Lordkipanidzé; Chantal Pharand; Erick Schampaert; Jacques Turgeon; Donald A Palisaitis; Jean G Diodati
Journal:  Eur Heart J       Date:  2007-06-14       Impact factor: 29.983

8.  Aspirin resistance and adverse clinical events in patients with coronary artery disease.

Authors:  Wai-Hong Chen; Xi Cheng; Pui-Yin Lee; William Ng; Jeanette Yat-Yin Kwok; Hung-Fat Tse; Chu-Pak Lau
Journal:  Am J Med       Date:  2007-07       Impact factor: 4.965

9.  The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study.

Authors:  Joseph DiChiara; Kevin P Bliden; Udaya S Tantry; Miruais S Hamed; Mark J Antonino; Thomas A Suarez; Oscar Bailon; Anand Singla; Paul A Gurbel
Journal:  Diabetes       Date:  2007-09-11       Impact factor: 9.461

10.  The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.

Authors:  Jill Belch; Angus MacCuish; Iain Campbell; Stuart Cobbe; Roy Taylor; Robin Prescott; Robert Lee; Jean Bancroft; Shirley MacEwan; James Shepherd; Peter Macfarlane; Andrew Morris; Roland Jung; Christopher Kelly; Alan Connacher; Norman Peden; Andrew Jamieson; David Matthews; Graeme Leese; John McKnight; Iain O'Brien; Colin Semple; John Petrie; Derek Gordon; Stuart Pringle; Ron MacWalter
Journal:  BMJ       Date:  2008-10-16
View more
  4 in total

1.  Prevalence of aspirin resistance in diabetic patients and its associated factors.

Authors:  Nor Halwani Habizal; Sanihah Abdul Halim; Shalini Bhaskar; Wan Mohamed Wan Bebakar; Jafri Malin Abdullah
Journal:  Malays J Med Sci       Date:  2015 Jan-Feb

Review 2.  Platelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery disease.

Authors:  Luis R Lopez; Kirk E Guyer; Ignacio Garcia De La Torre; Kelly R Pitts; Eiji Matsuura; Paul Rj Ames
Journal:  World J Diabetes       Date:  2014-04-15

3.  Younger age, higher body mass index and lower adiponectin concentration predict higher serum thromboxane B2 level in aspirin-treated patients with type 2 diabetes: an observational study.

Authors:  Agnieszka Kaplon-Cieslicka; Marek Postula; Marek Rosiak; Michal Peller; Agnieszka Kondracka; Agnieszka Serafin; Ewa Trzepla; Grzegorz Opolski; Krzysztof J Filipiak
Journal:  Cardiovasc Diabetol       Date:  2014-08-15       Impact factor: 9.951

4.  Evaluation of inflammatory conditions associated with aspirin resistance.

Authors:  Emre Yalcinkaya; Murat Celik
Journal:  Ups J Med Sci       Date:  2014-05-16       Impact factor: 2.384
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.